基于靶向细胞内抗原的TCR模拟纳米抗体的嵌合抗原受体T细胞疗法用于实体癌治疗。 - Suppr

CAR-T cell therapy based on a TCR mimic nanobody targeting an intracellular antigen for solid cancers.

作者信息

Lin Qingqing, Jin Shi, Wang Mingjun

机构信息

Department of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen International Biological Valley-Life Science Industrial Park, Dapeng New District, Shenzhen, China.

Shenzhen Innovation Immunotechnology Co., Ltd., Shenzhen International Biological Valley-Life Science Industrial Park, Dapeng New District, Shenzhen, China.

出版信息

Mol Ther Oncol. 2025 Feb 18;33(1):200948. doi: 10.1016/j.omton.2025.200948. eCollection 2025 Mar 20.

DOI:10.1016/j.omton.2025.200948

PMID:40041799

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11876872/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aad5/11876872/4632b1eea741/gr1.jpg

相似文献

CAR-T cell therapy based on a TCR mimic nanobody targeting an intracellular antigen for solid cancers.基于靶向细胞内抗原的TCR模拟纳米抗体的嵌合抗原受体T细胞疗法用于实体癌治疗。

Mol Ther Oncol. 2025 Feb 18;33(1):200948. doi: 10.1016/j.omton.2025.200948. eCollection 2025 Mar 20.

CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer.基于靶向人乳头瘤病毒16型E6的T细胞受体模拟纳米抗体的嵌合抗原受体T细胞对宫颈癌具有抗肿瘤活性。

Mol Ther Oncol. 2024 Oct 9;32(4):200892. doi: 10.1016/j.omton.2024.200892. eCollection 2024 Dec 19.

Nanobody-based CAR T cells targeting intracellular tumor antigens.基于纳米抗体的针对细胞内肿瘤抗原的 CAR T 细胞。

Biomed Pharmacother. 2022 Dec;156:113919. doi: 10.1016/j.biopha.2022.113919. Epub 2022 Oct 27.

Nanobody-based CAR-T cells for cancer immunotherapy.用于癌症免疫治疗的基于纳米抗体的嵌合抗原受体T细胞。

Biomark Res. 2022 Apr 25;10(1):24. doi: 10.1186/s40364-022-00371-7.

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.基于 CRISPR/Cas9 技术设计的纳米抗体嵌合抗原受体 T 细胞用于实体瘤免疫治疗。

Signal Transduct Target Ther. 2021 Feb 25;6(1):80. doi: 10.1038/s41392-021-00462-1.

MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity.MAGE-A4 pMHC 靶向 CAR-T 细胞利用 TCR 机制显著改善了体内功能，同时保留了抗原特异性。

J Immunother Cancer. 2024 Nov 20;12(11):e010248. doi: 10.1136/jitc-2024-010248.

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.通过基于纳米抗体的嵌合抗原受体靶向前列腺癌细胞上前列腺特异性膜抗原的工程化人 Jurkat 细胞。

Iran Biomed J. 2020 Mar;24(2):81-8. doi: 10.29252/ibj.24.2.81. Epub 2019 Oct 23.

B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.B7-H3 靶向嵌合抗原受体 Epstein-Barr 病毒特异性 T 细胞为 B7-H3 阳性实体瘤提供了一种肿瘤不可知的现货治疗方法。

Cancer Res Commun. 2024 Jun 4;4(6):1410-1429. doi: 10.1158/2767-9764.CRC-23-0538.

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.树突/肿瘤融合细胞疫苗增强基于纳米抗体的 CAR-T 细胞对实体瘤的疗效。

Theranostics. 2023 Sep 18;13(14):5099-5113. doi: 10.7150/thno.84946. eCollection 2023.

Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.双靶点 CAR T 细胞治疗卵巢癌：MUC16 CAR T 细胞分泌双特异性 T 细胞衔接抗体，靶向细胞内肿瘤抗原 WT1

Cancer Immunol Immunother. 2023 Nov;72(11):3773-3786. doi: 10.1007/s00262-023-03529-w. Epub 2023 Aug 27.

本文引用的文献

Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs).解锁细胞内肿瘤靶点：基于抗体的T细胞受体模拟物（TCRm）疗法在T细胞衔接器（TCE）和抗体药物偶联物（ADC）中的独特作用。

Cancers (Basel). 2024 Nov 8;16(22):3776. doi: 10.3390/cancers16223776.

Mol Ther Oncol. 2024 Oct 9;32(4):200892. doi: 10.1016/j.omton.2024.200892. eCollection 2024 Dec 19.

From bench to bedside: the history and progress of CAR T cell therapy.从实验室到临床：嵌合抗原受体 T 细胞疗法的历史与进展。

Front Immunol. 2023 May 15;14:1188049. doi: 10.3389/fimmu.2023.1188049. eCollection 2023.

Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.鉴定和承诺一种 TCR 模拟抗体用于肝癌的癌症免疫治疗。

Sci Rep. 2022 Jul 15;12(1):12068. doi: 10.1038/s41598-022-15946-5.

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.开发针对 NY-ESO-1/HLA-A2 的 TCR 样抗体和嵌合抗原受体用于癌症免疫治疗。

J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004035.

A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex.一种针对 HPV-16 E7-表位 p11-19/HLA-A*02:01 复合物的 TCR 模拟单克隆抗体。

PLoS One. 2022 Mar 17;17(3):e0265534. doi: 10.1371/journal.pone.0265534. eCollection 2022.

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.卡泊单抗用于成年获得性血栓性血小板减少性紫癜患者。

Ther Adv Hematol. 2020 Feb 7;11:2040620720902904. doi: 10.1177/2040620720902904. eCollection 2020.

Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.针对表达突变型 p53 的肿瘤，使用针对野生型抗原的 T 细胞受体样抗体。

Nat Commun. 2019 Nov 26;10(1):5382. doi: 10.1038/s41467-019-13305-z.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR-T cell therapy based on a TCR mimic nanobody targeting an intracellular antigen for solid cancers.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献